Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9178752 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1MEN1CYP2C9HPGD | |
| SCHEMBL1385783 | 0.82 | ALDH1A1 (0.61) | ALDH1A1MEN1CYP2C9HPGDKMT2A | |
| SCHEMBL9311653 | 0.80 | SIGMAR1 (0.57) | SMN1; SMN2ALDH1A1MEN1CYP2C9HPGD | |
| SCHEMBL3609789 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1MEN1CYP2C9HPGD | |
| SCHEMBL9313159 | 0.79 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1MEN1CYP2C9HPGD | |
| SCHEMBL27609154 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1MEN1CYP2C9HPGD | |
| SCHEMBL9311637 | 0.77 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1MEN1CYP2C9HPGD | |
| SCHEMBL30568040 | 0.76 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1MEN1CYP2C9HPGD | |
| SCHEMBL28115195 | 0.76 | SIGMAR1 (0.57) | SMN1; SMN2ALDH1A1MEN1CYP2C9HPGD | |
| SCHEMBL265014 | 0.75 | ALDH1A1 (0.62) | ALDH1A1MEN1CYP2C9HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | SMN1; SMN2 3162/4885ALDH1A1 2810/4885MEN1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.